← Home
Abbott Laboratories
-12.77%
Healthcare & biotech / Diversified healthcare products
🔥 Video Insights
Abbott Laboratories’ share price has declined and now trades below recent highs, reflecting slowing growth and weaker sentiment. Despite this, the company continues to generate solid revenue and strong cash flow, with operating margins remaining healthy. Recent results showed softer sales in certain segments, while growth in others could not fully offset the decline. Earnings expectations have moderated, which explains part of the market reaction. From a value perspective, the stock looks more attractive than before, but not deeply discounted given its stable profile. Dividends have increased consistently over many years, supported by reliable cash generation. Risks include slower growth, segment imbalances, and execution challenges in new initiatives. A recovery could come if growth stabilizes and margins improve, but the timeline remains uncertain. This review is for informational and educational purposes only, not a financial advice.